keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28730687/efficacy-of-abatacept-in-patients-with-rheumatoid-arthritis-as-assessed-by-magnetic-resonance-imaging-of-bilateral-hands
#1
Yuji Kukida, Akiko Kasahara, Takahiro Seno, Takuya Inoue, Risa Sagawa, Takashi Kida, Amane Nakabayashi, Hidetake Nagahara, Ken Murakami, Toshifumi Sugitani, Satoshi Morita, Hirotoshi Ito, Ryo Oda, Hiroyoshi Fujiwara, Masataka Kohno, Yutaka Kawahito
AIM: To examine the efficacy of abatacept in patients with rheumatoid arthritis (RA) using magnetic resonance imaging (MRI) of bilateral hands. METHOD: This prospective study included 35 RA patients. MRI of bilateral hands was performed at baseline and after 12 months of treatment with intravenous abatacept. MRI images were scored for synovitis, osteitis, erosion and joint space narrowing (JSN) according to the RA MRI Scoring System (RAMRIS). The primary endpoint was the change in RAMRIS score from baseline...
July 21, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28728565/identification-of-differential-co-expressed-gene-networks-in-early-rheumatoid-arthritis-achieving-sustained-drug-free-remission-after-treatment-with-a-tocilizumab-based-or-methotrexate-based-strategy
#2
Xavier M Teitsma, Johannes W G Jacobs, Michal Mokry, Michelle E A Borm, Attila Pethö-Schramm, Jacob M van Laar, Johannes W J Bijlsma, Floris P J Lafeber
BACKGROUND: Methotrexate is endorsed to be used as first-line treatment in rheumatoid arthritis (RA). However, a large proportion of patients need additional treatment with a biological disease-modifying anti-rheumatic drug (DMARD) to adequately suppress their disease activity. A better understanding of genotypes could help to distinguish between patients with different pathogenic mechanisms. The aim of this study was therefore to identify networks of genes within DMARD-naive early RA patients associated with achieving sustained drug-free remission (sDFR) after initiating tocilizumab plus methotrexate, tocilizumab, or methotrexate therapy...
July 20, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28726020/patterns-of-circulatory-and-peripheral-blood-mononuclear-cytokines-in-rheumatoid-arthritis
#3
Fawaz Y Azizieh, Khaled Al Jarallah, Diaa Shehab, Renu Gupta, Kamaludin Dingle, Raj Raghupathy
An imbalance in pro- and anti-inflammatory cytokines is suggested to contribute to tissue damage in rheumatoid arthritis (RA). This study was aimed at investigating profiles of cytokines in circulation and cytokines produced by mitogen-stimulated peripheral blood mononuclear cells (PBMC) in RA patients and healthy controls, and to explore correlations of cytokines with disease activity. Our aim was to identify patterns of cytokine expression as possible indicators of disease activity. Levels of plasma cytokines and PBMC-secreted cytokines were estimated in 26 female RA patients and 28 controls...
July 19, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28725981/certolizumab-pegol-was-effective-for-treating-residual-synovitis-after-total-knee-arthroplasty-in-a-patient-with-rheumatoid-arthritis-therapeutic-monitoring-by-ultrasound
#4
Shin-Ya Kawashiri, Tohru Michitsuji, Atsushi Kawakami
We present the case of a 59-year-old female who developed rheumatoid arthritis in 2007. Right total knee arthroplasty (TKA) was performed in 2008. Although she was treated with methotrexate (MTX) after the operation, this treatment was insufficient. Infliximab (IFX) was introduced in 2001, and she achieved clinical remission. Left TKA was performed in October 2014. Because active synovitis was not detected by ultrasound after the operation, IFX was discontinued. She had been treated with MTX 8 mg weekly. However, arthralgia of the bilateral knees developed in March 2015...
July 19, 2017: Journal of Medical Ultrasonics
https://www.readbyqxmd.com/read/28725502/universal-2-wrist-arthroplasty-in-rheumatoid-arthritis
#5
Sandra Pfanner, Giovanni Munz, Giulia Guidi, Massimo Ceruso
Purpose  The aim of this study was to evaluate the mid- to long-term outcomes and complications in patients affected by rheumatic diseases treated with the Universal 2 (U2) total wrist arthroplasty (TWA). Methods  We reviewed, in a retrospective, noncontrolled cohort study, 22 patients affected by rheumatoid arthritis (RA), who underwent U2 total wrist replacement between March 2003 and January 2014 for the treatment of 23 rheumatoid wrists with the aim of obtaining the remission of pain and a range of motion (ROM) useful for daily activities, according to the patients' demands, as an alternative to total wrist arthrodesis...
August 2017: Journal of Wrist Surgery
https://www.readbyqxmd.com/read/28714991/resolution-of-inflammation-by-interleukin-9-producing-type-2-innate-lymphoid-cells
#6
Simon Rauber, Markus Luber, Stefanie Weber, Lisa Maul, Alina Soare, Thomas Wohlfahrt, Neng-Yu Lin, Katharina Dietel, Aline Bozec, Martin Herrmann, Mark H Kaplan, Benno Weigmann, Mario M Zaiss, Ursula Fearon, Douglas J Veale, Juan D Cañete, Oliver Distler, Felice Rivellese, Costantino Pitzalis, Markus F Neurath, Andrew N J McKenzie, Stefan Wirtz, Georg Schett, Jörg H W Distler, Andreas Ramming
Inflammatory diseases such as arthritis are chronic conditions that fail to resolve spontaneously. While the cytokine and cellular pathways triggering arthritis are well defined, those responsible for the resolution of inflammation are incompletely characterized. Here we identified interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as the mediators of a molecular and cellular pathway that orchestrates the resolution of chronic inflammation. In mice, the absence of IL-9 impaired ILC2 proliferation and activation of regulatory T (Treg) cells, and resulted in chronic arthritis with excessive cartilage destruction and bone loss...
July 17, 2017: Nature Medicine
https://www.readbyqxmd.com/read/28713386/impairment-of-granzyme-b-producing-regulatory-b-cells-correlates-with-exacerbated-rheumatoid-arthritis
#7
Liling Xu, Xu Liu, Hongjiang Liu, Lei Zhu, Huaqun Zhu, Jian Zhang, Limin Ren, Pingzhang Wang, Fanlei Hu, Yin Su
Hyperactivated B cells have been demonstrated the contribution to the development of rheumatoid arthritis (RA). While the recognition of the negative regulatory function of B cells further promoted our understanding of their pathogenic role in RA. Recently, a new population of granzyme B (GrB)-producing B cells was identified, which was proved to be involved in cancer and infectious diseases. However, their characteristics and roles in RA remain to be elucidated. In the present study, we aim to further characterize whether B cells could produce GrB and reveal their potential role in the pathogenesis of RA...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28711461/prevalence-of-comorbidities-in-rheumatoid-arthritis-and-evaluation-of-their-monitoring-in-clinical-practice-the-spanish-cohort-of-the-comora-study
#8
Alejandro Balsa, Leticia Lojo-Oliveira, Mercedes Alperi-López, María García-Manrique, Carmen Ordóñez-Cañizares, Lorena Pérez, Virginia Ruiz-Esquide, Alfonso Corrales, Javier Narváez, José Rey-Rey, Carlos Rodríguez-Lozano, Soledad Ojeda, Santiago Muñoz-Fernández, Joan M Nolla, José García-Torrón, Fernando Gamero, Rosario García-Vicuña, Blanca Hernández-Cruz, José Campos, José Rosas, José Francisco García-Llorente, Antonio Gómez-Centeno, Rafael Cáliz, Raimon Sanmartí, Alberto Bermúdez, Lydia Abasolo-Alcázar, Antonio Fernández-Nebro, Luis Rodríguez-Rodríguez, Carlos Marras, Miguel Ángel González-Gay, Ihsane Hmamouchi, Emilio Martín-Mola
OBJECTIVES: To describe the prevalence of comorbidities in patients with RA in Spain and discuss their management and implications using data from the Spanish cohort of the multinational study on COMOrbidities in Rheumatoid Arthritis (COMORA). METHODS: This is a national sub-analysis of the COMORA study. We studied the demographics and disease characteristics of 200 adults patients diagnosed with RA (1987 ACR), and routine practices for screening and preventing the following selected comorbidities: cardiovascular, infections, cancer, gastrointestinal, pulmonary, osteoporosis and depression...
July 12, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28710095/acute-coronary-syndrome-in-new-onset-rheumatoid-arthritis-a-population-based-nationwide-cohort-study-of-time-trends-in-risks-and-excess-risks
#9
Marie Holmqvist, Lotta Ljung, Johan Askling
BACKGROUND: Acute coronary syndrome (ACS) and other cardiovascular diseases are the main drivers of the increased morbidity and preterm mortality in rheumatoid arthritis (RA). ACS in RA has been linked to inflammation and RA severity. During recent years and with new therapeutic options and treat-to-target strategies, increasing efforts have been made to reach RA remission as soon as possible after diagnosis, and the average level of RA disease activity has declined. Whether this has resulted in declining excess risks for RA comorbidities remains unclear...
July 14, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28701065/predictors-of-biologic-discontinuation-due-to-insufficient-response-in-patients-with-rheumatoid-arthritis-who-achieved-clinical-remission-with-biologic-treatment-a-multicenter-observational-cohort-study
#10
Shuji Asai, Takayoshi Fujibayashi, Takeshi Oguchi, Masahiro Hanabayashi, Masatoshi Hayashi, Hiroyuki Matsubara, Takayasu Ito, Yuichiro Yabe, Tsuyoshi Watanabe, Yuji Hirano, Yasuhide Kanayama, Atsushi Kaneko, Takefumi Kato, Hideki Takagi, Nobunori Takahashi, Koji Funahashi, Toki Takemoto, Nobuyuki Asai, Tatsuo Watanabe, Naoki Ishiguro, Toshihisa Kojima
OBJECTIVE: This study aimed to investigate predictors of biologic discontinuation due to insufficient response as a surrogate for relapse in patients with rheumatoid arthritis (RA) who achieved clinical remission with biologic treatment. METHODS: This study was performed based on data from a multicenter registry, and included 404 patients who achieved clinical remission within the first year of treatment with their first biologic. Cumulative retention rate of the first biologic was estimated using Kaplan-Meier curves, and the impact of patient characteristics on biologic discontinuation was assessed with Cox proportional hazards models...
July 13, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28695274/real-world-clinical-experience-of-biological-disease-modifying-anti-rheumatic-drugs-in-malaysia-rheumatoid-arthritis-patients
#11
Bee Eng Tan, Ai Lee Lim, Sow Lai Kan, Chong Hong Lim, Esther Ee Ling Tsang, Shereen Suyin Ch'ng, Nadiah Mohd Noor, Nurulraziquin Mohd Jamid, Cheng Lay Teh, Rachel Joshua Thundyil, Yet Lin Loh, Hwee Cheng Chong, Swee Gaik Ong, Asmahan Mohamed Ismail, Yvonne Y L Lee, Suk Chyn Gun
The effect of biologic disease modifying anti-rheumatic drugs (bDMARDs) in treating rheumatoid arthritis (RA) in real-world clinical practice remains unknown in Southeast Asia. We aimed to assess the efficacy and safety of bDMARDs among Malaysian RA patients treated in routine clinical practice. A retrospective medical chart review of RA patients from 11 government hospitals were conducted from January 2003 to January 2014. A standardized questionnaire was used to abstract patient's demographic, clinical and treatment data...
July 10, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28692794/despite-early-improvement-patients-with-rheumatoid-arthritis-still-have-impaired-grip-force-5-years-after-diagnosis
#12
Maria Rydholm, Christina Book, Ingegerd Wikström, Lennart Jacobsson, Carl Turesson
OBJECTIVE: Objective measures of function are important in rheumatoid arthritis (RA). The objective of this study was to investigate grip strength in patients with early RA. METHODS: An inception cohort of 225 patients with early RA was followed according to a structured protocol. Average and peak grip force values (Grippit; AB Detektor, Gothenburg, Sweden) of the dominant hand were evaluated and compared to the expected, based on age- and sex-specific reference values from the literature...
July 10, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28692770/impact-of-stopping-tumor-necrosis-factor-inhibitors-on-rheumatoid-arthritis-patients-burden-of-disease
#13
Marjan Ghiti Moghadam, Peter M Ten Klooster, Harald E Vonkeman, Eva L Kneepkens, Ruth Klaasen, Jan N Stolk, Ilja Tchetverikov, Simone A Vreugdenhil, Jan M van Woerkom, Yvonne P M Goekoop-Ruiterman, Robert B M Landewé, Piet L C M van Riel, Mart A F J van de Laar, Tim L Jansen
OBJECTIVE: To determine the impact of stopping tumor necrosis factor inhibitor (TNFi) treatment on patient-reported outcomes (PROs) of physical and mental health status, health utility, pain, disability and fatigue in patients with established rheumatoid arthritis (RA). METHODS: In the pragmatic 12-month POET trial, 817 RA patients with ≥6 months of remission or stable low disease activity were randomized 2:1 to stopping or continuing TNFi. In case of flare, TNFi was restarted at the discretion of the rheumatologist...
July 10, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28688467/prediction-of-response-to-targeted-treatment-in-rheumatoid-arthritis
#14
REVIEW
C A Wijbrandts, P P Tak
Rheumatoid arthritis is an autoimmune syndrome presenting with chronic inflammation of the joints. Patients with the same diagnosis can present with different phenotypes. In some patients severe joint inflammation and early joint destruction are observed, whereas a milder phenotype can be seen in others. Conversely, patients with the same signs and symptoms may exhibit different immunological and molecular abnormalities. Since the introduction of early treatment in clinical practice, the treat to target principle, and new medicines such as biologic disease-modifying antirheumatic drugs, clinical remission can be achieved early in the disease course, albeit not in all patients...
July 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28679993/iatrogenic-immunodeficiency-associated-epstein-barr-virus-ebv-negative-natural-killer-cell-lymphoproliferative-disorder-in-a-patient-undergoing-rheumatoid-arthritis-therapy
#15
Tomoyuki Uchida, Morihiro Inoue, Jian Hua, Shogo Tajima, Yasunori Ota, Masao Hagihara
Here we present a patient with rheumatoid arthritis (RA), who was suspected to have developed malignant lymphoma during immunosuppressive therapy 5 years earlier. She temporarily achieved remission after discontinuing therapy; however, her disease worsened with remittent fever and splenomegaly. Splenic biopsy demonstrated infiltration by abnormal cells, which were positive for CD56 and T cell intracytoplasmic antigen, but negative for CD3 and Epstein-Barr virus (EBV) -encoded RNA. Cytogenetic analysis of bone marrow and lumbar spine tumor revealed common complex karyotype abnormalities...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28679990/myelodysplastic-syndrome-with-neutrophilic-dermatosis-successfully-treated-with-azacitidine
#16
Daisuke Kudo, Misayo Shimizu, Akihiro Kuroda, Takuya Suyama, Atsushi Shinagawa, Syusaku Ito
A 66-year-old male underwent prednisolone (PSL) therapy of 13 mg/day for rheumatoid arthritis (RA). Antiphospholipid antibody syndrome, neutrophilic dermatosis (ND), and myelodysplastic syndrome (MDS) developed. Treatment of MDS required red cell concentrate transfusion, and second courses of azacitidine therapy (75 mg/m(2) daily, intravenous injection for 7 consecutive days) led to hematologic remission. Furthermore, ND improved early after the start of azacitidine therapy, making it possible to decrease the dose of PSL...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28676287/analysis-of-effectiveness-safety-and-optimization-of-tocilizumab-in-a-cohort-of-patients-with-rheumatoid-arthritis-in-clinical-practice
#17
Natalia Mena-Vázquez, Sara Manrique-Arija, Marta Rojas-Giménez, Inmaculada Ureña-Garnica, Francisco G Jiménez-Núñez, Antonio Fernández-Nebro
OBJECTIVE: To evaluate the effectiveness and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in clinical practice, establishing the optimized regimen and switching from intravenous (IV) to subcutaneous (SC) therapy. MATERIAL AND METHODS: Retrospective observational study. We included 53 RA patients treated with TCZ. The main outcome was TCZ effectiveness at week 24. Secondary outcome variables included effectiveness at week 52, therapeutic maintenance, physical function and safety...
July 1, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28676129/evaluation-of-newly-proposed-remission-cut-points-for-disease-activity-score-in-28-joints-das28-in-rheumatoid-arthritis-patients-upon-il-6-pathway-inhibition
#18
M Schoels, F Alasti, J S Smolen, D Aletaha
BACKGROUND: Stringent remission criteria are crucial in rheumatoid arthritis (RA) assessment. Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions, because of its association with significant residual disease activity, partly due to high weighting of acute-phase reactants (APR). New, more stringent cut-points for DAS28-remission have recently been proposed that are suggested to reflect remission by clinical and simplified disease activity indices (clinical disease activity index (CDAI), simple disease activity index (SDAI))...
July 4, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28664281/-psoriatic-arthritis-current-therapeutic-standards
#19
REVIEW
M Köhm, F Behrens
Psoriatic arthritis (PsA) is a heterogeneous immune-mediated disease that usually involves the skin and joints but can also affect the entheses, spine and other extra-articular structures. Furthermore, it can be coupled with associated comorbidities. The selection of a patient-oriented and effective therapy is based on the extent of various manifestations of the disease as well as further influencing factors. Various recommendations for selection and control are available for deciding on a suitable treatment...
June 29, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28649878/safety-and-effectiveness-of-tacrolimus-add-on-therapy-for-rheumatoid-arthritis-patients-without-an-adequate-response-to-biological-disease-modifying-anti-rheumatic-drugs-dmards-post-marketing-surveillance-in-japan
#20
Tsutomu Takeuchi, Kota Ishida, Katsuhisa Shiraki, Takashi Yoshiyasu
OBJECTIVES: Post-marketing surveillance (PMS) was conducted to assess the safety and effectiveness of tacrolimus (TAC) add-on therapy for patients with rheumatoid arthritis (RA) and an inadequate response to biological disease-modifying anti-rheumatic drugs (DMARDs). METHODS: Patients with RA from 180 medical sites across Japan were registered centrally with an electronic investigation system. The observational period was 24 weeks from the first day of TAC administration concomitantly with biological DMARDs...
June 26, 2017: Modern Rheumatology
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"